Nevertheless, this is a milestone finding as it is the first genetic study that has provided both functional and structural evidence demonstrating endogenous SPL is involved in the EAE disease progression and that blocking its activity in adult ameliorates MS-like disease progression and neural pathology. The gene discussed is SGPL1; the disease is myeloid sarcoma.